Compare MAMA & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAMA | BBNX |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 602.1M | 493.1M |
| IPO Year | 2011 | 2025 |
| Metric | MAMA | BBNX |
|---|---|---|
| Price | $17.74 | $17.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $19.00 | ★ $23.80 |
| AVG Volume (30 Days) | 467.2K | ★ 1.4M |
| Earning Date | 04-14-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 44.44 | ★ 78.95 |
| EPS | ★ 0.05 | N/A |
| Revenue | $95,420,129.00 | ★ $100,251,000.00 |
| Revenue This Year | $31.09 | $34.90 |
| Revenue Next Year | $16.12 | $34.63 |
| P/E Ratio | $352.20 | ★ N/A |
| Revenue Growth | ★ 95.54 | 53.94 |
| 52 Week Low | $7.90 | $8.80 |
| 52 Week High | $21.00 | $32.71 |
| Indicator | MAMA | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 50.81 | 59.08 |
| Support Level | $17.37 | $16.02 |
| Resistance Level | $19.52 | $18.20 |
| Average True Range (ATR) | 0.74 | 1.23 |
| MACD | -0.07 | 0.09 |
| Stochastic Oscillator | 48.42 | 99.28 |
Mama's Creations Inc manufactures and markets fresh deli-prepared foods distributed through grocery, mass, club, and convenience stores across the United States. Its product portfolio includes refrigerated prepared foods such as meatballs, meatloaf, sausage products, and pasta and rice entrees. The products are principally sold to supermarkets, club chains, mass-market retailers, and food distributors. The brand of the company includes Mama's Creations, Mama's Mancini's, The Olive Branch, Creative Salads, and others.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.